focus -WSS

focus

author：hotspot 2025-09-28 01:35:05 - browse：8779

Sorrento Therapeutics — ARIANA DREHSLER/AFP via Getty Images

SAN DIEGO — U.S. legislation that seeks to restrict American biotechs from working with certain Chinese firms and suppliers is for now just that — a proposal, not a law. But the looming bill’s impact was clearly visible at this year’s meeting of the industry’s largest trade group.

A number of biotech companies in attendance at the meeting of the Biotechnology Innovation Organization told STAT they’re actively looking to strike deals with U.S.-based drug manufacturers rather than companies named in the legislation, even though doing so will be more costly. An executive at a U.S.-based contract development and manufacturing organization, or CDMO, who spoke on condition of anonymity, said that “month to month, new business has gone through the roof.”

Meanwhile, some Chinese suppliers not named in the bill are paradoxically drawing increased interest from biotechs — while hearing from some customers worried those manufacturers could be blacklisted in the future.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Canadian Prime Minister Justin Trudeau separating from wife, Sophie

explore

WSS

‘Oppenheimer’ and the risks of AI in health care

No plane should take off without an EpiPen onboard

No plane should take off without an EpiPen onboard

Rise in cancer among younger people worries and puzzles doctors

Device maker Teleflex to acquire urology company for $600M

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

leisure time

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

DIEP, the 'gold standard' of breast reconstruction, is under threat

The battle over 'scope creep' and who gets to be called 'doctor'

Virginia high school admissions case could be legal follow

Democrats decry new health bill for going easy on private equity

Virginia high school admissions case could be legal follow

Roche’s Alnylam deal shows drug firms interested in heart drugs

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

The battle over 'scope creep' and who gets to be called 'doctor'

Malaria cases in Florida and Texas: Here’s what you need to know

Wildfire pollution widens asthma inequities on Long Island

focus

Mitch McConnell episode has important public health takeaway

In the gardens at Boston Children's Hospital, families find sanctuary

Mega Millions pot grows to $1.25 billion after no winner

Infectious disease expert Jeanne Marrazzo assumes Fauci role

UHS says company favors patients whose insurance pays more

The high personal cost of affirmative action for Black doctors

explore

focus

explore

knowledge